Navigation Links
Accumetrics Announces Publication of GRAVITAS Primary Results in JAMA
Date:3/15/2011

gents or repeated testing to a specific target of reactivity."

The article reports that 41% of patients in the GRAVITAS trial had high on-treatment platelet reactivity after receiving Plavix®. This is consistent with previous studies that show that up to 1 in 3 patients may not be responding adequately to their antiplatelet therapy. Numerous factors are associated with low platelet response, including pre-existing health conditions such as diabetes, interference from other medications, non compliance and genetics.

"GRAVITAS underscores the need to develop more individualized treatment strategies for cardiovascular patients," said Timothy I. Still, President and CEO of Accumetrics. "As more antiplatelet treatment options become available, the VerifyNow System continues to help clinicians better assess a patient's response to therapy."

The VerifyNow System is widely used in various clinical settings where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.

(1)  Price MJ, Berger PB, Teirstein PS, et al. Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. JAMA.2011;305[11]1097-1105.

AboutAccumeicsAccumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy-to-use platform to help physicians determine an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient®) and clopidogrel (Plavix®)), and GP IIb/IIIa inhibitors (e.g. ReoPro® and Integrilin®), the VerifyNow Sy
'/>"/>

SOURCE Accumetrics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Timothy I. Still Appointed CEO at Accumetrics
2. Accumetrics Appoints John J. Young, MD Chief Medical Officer
3. Andrew Chisholm Appointed Vice President, Sales and Corporate Accounts at Accumetrics
4. Accumetrics, Inc. Announces European Distribution Channels for France, Austria, Switzerland, Netherlands, Belgium and Luxembourg
5. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
6. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
7. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
8. Anesiva Announces Second Quarter 2008 Financial Results and Update
9. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
10. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
11. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... today announced that it will release fourth quarter and ... March 10, 2015 after the close of the U.S. ... and webcast on Tuesday, March 10, 2015 at 4:30 ... results and recent corporate developments. For both ...
(Date:3/2/2015)... Massachusetts (PRWEB) March 02, 2015 Outside ... services, today announced the addition of Debbie Casey as ... capabilities in the healthcare space. , Debbie ... most of which with Fresenius Medical Care North America ... leverage her extensive experience to work with Outside GC’s ...
(Date:2/27/2015)... GERMANTOWN, Md. and SUMMERLAND, British ... Corporation (NYSE: XON ), a leader ... an agreement to acquire  Okanagan Specialty Fruits (OSF), ... apple , the world,s first non-browning apple. Through ... trees yielding fruit that is more appetizing and convenient ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
Breaking Biology Technology:Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 2Outside GC Expands Healthcare Team 2Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... This release is available in Spanish . ... leading in Spain the European project within the VII Framework ... buildings which host large numbers of people, such as sports ... by the management and optimisation of energy in its three ...
... 5, 2011 Sangamo BioSciences, Inc. (Nasdaq: SGMO ... will provide an update on the progress of Sangamo,s ZFP ... strategy at 12:30 pm PT (3:30 pm ET) on Thursday, ... Conference which will be held in San Francisco. ...
... HOUSTON, Jan. 5, 2011 International energy pricing agency ... expansion into US and Canadian wood chip pricing complements ... broader European biomass indexation. " Argus understands ... to be at the forefront, providing transparency to emerging biomass ...
Cached Biology Technology:Tecnalia leads the integration of energy efficiency in sports facilities 2Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference 2Argus Launches North American Wood Chip Price Assessments 2
(Date:2/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT METHOD ... a new groundbreaking payment method. Payment accounts may be ... only be accessed if both the speech (the word ...
(Date:2/18/2015)... 2015  Cepheid (NASDAQ: CPHD ) today announced ... and invited investors to participate via webcast. , Cowen ... Tuesday, March 3, 2015 at 11.20 a.m. Eastern Time ... FL Wednesday, March 4, 2015 at 10.25 a.m. ... live webcasts for these events, please visit Cepheid,s website at ...
(Date:2/12/2015)...   MedNet Solutions , a global life ... systems, has recently bolstered its iMedNet™ ... iMedNet as the eClinical solution of ... consultants.  Building on the Program,s existing benefits (including ... co-marketing opportunities), MedNet,s new and improved program provides ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... intimately familiar with the awe-inspiring photos of space shuttle launches ... But how many people have paused for even a second ... a two-week space shuttle mission or are living for months ... book The Astronaut,s Cookbook Tales, Recipes, and More ...
... 13 BIO-key International, Inc. (OTC Bulletin Board: BKYI), ... identification solutions, today reported results for the third quarter ... The Company,s results reflected operating profitability for each quarter ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ) , As a result of ...
... DALLAS Nov. 12, 2009 UT Southwestern ... to date for basic and patient-oriented research from the ... billion stimulus package President Barack Obama signed into law ... the National Science Foundation (NSF) and the National Institutes ...
Cached Biology News:The astronaut's cookbook 2BIO-key(R) Reports Fourth Consecutive Quarter of Operating Profitability 2BIO-key(R) Reports Fourth Consecutive Quarter of Operating Profitability 3BIO-key(R) Reports Fourth Consecutive Quarter of Operating Profitability 4BIO-key(R) Reports Fourth Consecutive Quarter of Operating Profitability 5BIO-key(R) Reports Fourth Consecutive Quarter of Operating Profitability 6UT Southwestern receives $42 million in Recovery Act stimulus funding 2UT Southwestern receives $42 million in Recovery Act stimulus funding 3
...
... Purity is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related research has ... of new radiolabeled ligands selected to keep ... wide range of products and services for ... 400 state-of-the-art radioligands. If you do not ...
... The Polymerase gene from Thermus ... expressed in E. coli, then highly ... It is used in the amplification ... PCR. The quality of the Taq ...
... iTaq DNA polymerase is an ... for both conventional and real-time ... supplied at a concentration of ... includes 5,000 units polymerase, 25 ...
Biology Products: